Results 131 to 140 of about 6,745,951 (330)

Characterising processes and outcomes of tailoring implementation strategies in healthcare: a protocol for a scoping review [version 2; peer review: 2 approved, 1 approved with reservations]

HRB Open Research, 2022
Background: Tailoring strategies to target the salient barriers to and enablers of implementation is considered a critical step in supporting successful delivery of evidence based interventions in healthcare.
Bianca Albers, Sheena M. McHugh, Nickola Pallin, Lauren Clack, Claire Kerins, Eimear Morrissey, Geoffrey M. Curran, Justin Presseau, Byron J. Powell, Cara C. Lewis, Fiona Riordan, Luke Wolfenden   +11 more
doaj  

How blockchain-timestamped protocols could improve the trustworthiness of medical science [PDF]

, 2016
Greg Irving, John Holden
openalex   +1 more source

Assessment of diversity-based approaches used by American Universities to increase recruitment and retention of biomedical sciences faculty members: a scoping review protocol [PDF]

, 2022
Britta Petersen, Sherli Koshy-Chenthittayil, Leslie A. Caromile   +2 more
openalex   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

730 Development and implementation of a peer evaluation teaching protocol in a large animal science program [PDF]

, 2017
E. Huff‐Lonergan, Joan E. Cunnick, Adrianne Johnson, Jodi A. Sterle   +3 more
openalex   +1 more source

Protocol for establishing and evaluating a public and patient panel for organisation science and management principles in healthcare [PDF]

, 2022
Claire Harnett, Nuala Ryan, Briga Hynes
openalex   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Fall prevention interventions for Hispanic/Latino older adults: a scoping review protocol

Frontiers in Public Health
BackgroundDespite the importance of fall prevention among older adults, limited research exists on interventions tailored to rapidly growing Hispanic/Latino populations in the United States.
Janet Lopez, Michael Joseph Dino, Chitra Banarjee, Chitra Banarjee, Ladda Thiamwong   +4 more
doaj   +1 more source

A transformative translational change programme to introduce genomics into healthcare: a complexity and implementation science study protocol [PDF]

, 2019
Natalie Taylor, Stephanie Best, Melissa Martyn, Janet C. Long, Kathryn N. North, Jeffrey Braithwaite, Clara Gaff   +6 more
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source